Loading...
•
Dec 31, 2020
Arrowhead Pharmaceuticals Q1 2021 Earnings Report
Reported first quarter fiscal year 2021 results, showing a decrease in revenue and a net loss.
Key Takeaways
Arrowhead Pharmaceuticals reported a decrease in revenue and a net loss for the first quarter of fiscal year 2021. The company is focused on developing RNAi therapeutics.
Submitted an IND application for ARO-ANG3 for mixed dyslipidemia.
Presented new clinical data from Phase 1/2 studies of ARO-APOC3 and ARO-ANG3 at the American Heart Association meetings.
Closed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, including $300 million upfront.
Presented new clinical data on ARO-AAT at The Liver Meeting Digital Experience.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...